Page 1

Sun Pharmaceutical Industries Limited SUN HOUSE , CTS No. 201 B / 1 , Western Express Highway , Goregaon ( E ) , Mumbai 400063 , India Tel .: ( 91-22 ) 4324 4324 Fax .: ( 91-22 ) 4324 4343 CIN : L24230GJ1993PLC019050 www.sunpharma.com SUN PHARMA FOR IMMEDIATE RELEASE Sun Pharma reports Q3FY21 results Q3 Gross Sales at Rs . 8,782 crores up 9 % YoY Q3 Net Profit at Rs . 1,852 crores up 103 % YoY Mumbai , January 29 , 2021 : Sun Pharmaceutical Industries Limited ( Reuters : SUN.BO , Bloomberg : SUNP IN , NSE : SUNPHARMA , BSE : 524715 ) reported financials for the 3rd quarter & nine month ending December 31st , 2020 . Highlights of Q3FY21 consolidated financials • Consolidated sales from operations at Rs . 8,782 crores , growth of 9.2 % over Q3 last year India sales at Rs . 2,753 crores , growth of 9.4 % compared to Q3 last year US finished dosage sales at US $ 374 million , growth of 7 % compared to Q3 last year Emerging Markets sales at US $ 204 million , up by 4.7 % over Q3 last year Rest of World sales at US $ 173 million , up by 11.7 % over Q3 last year R & D investments at Rs . 560 crores ( 6.4 % of sales ) compared to Rs . 527 crores ( 6.6 % of sales ) for Q3FY20 EBITDA at Rs . 2,351 crores , up by 36.3 % over Q3 last year , with resulting EBITDA margin of 26.8 % Net profit for Q3 at Rs . 1,852 crores , up 102.8 % over Q3 last year , with resulting net profit margin of 21.1 % Highlights of 9mFY21 consolidated financials • Consolidated sales from operations at Rs . 24,708 crores , up by 1.9 % over same period last year . India sales at Rs . 7,672 crores , up by 4.5 % over 9 months last year . US finished dosage sales at US $ 991 million , a decline of 11 % over 9 month last year . Sales for 9 month last year included a one - time contribution from the special business in US and hence the numbers are not strictly comparable . Emerging Markets sales at US $ 587 million , flat over 9 month last year . • • Rest of World sales at US $ 486 million , flat over 9 month last year . • EBITDA at Rs . 6,176 crores up by 18.3 % over 9 month last year , with resulting EBITDA margin of 25 % . Excluding the exceptional items , adjusted net profit for 9mFY21 was at Rs . 4,589 crores , up 36.4 % YoY , with resulting net profit margin at 18.6 % . Reported net profit for 9mFY21 was at Rs . 2,010 crores . These results were taken on record by the Board of Directors at a meeting held today . The Board has proposed an interim dividend of Rs . 5.50 per share for the year FY21 . Dilip Shanghvi , Managing Director of the Company said , " Our Q3 performance reflects continued profitable business growth in a market that is gradually recovering from the impact of the global pandemic . Most of our businesses have done well over Q3 last year . Our global specialty sales have continued to show an improving trend and have crossed pre - Covid levels . Global Ilumya sales for nine months ended Dec'20 have already crossed last full year's sales . " Debt Repayment The company has repaid debt of about US $ 490 million in 9mFY21 compared to the debt as of March 31 , 2020 . Registered Office : SPARC , Tandalja , Vadodara - 390 012. India Reaching People . Touching Lives